


PRODUCT INFORMATION



Propentofylline

Item No. 29431

CAS Registry No.: 55242-55-2
Formal Name: 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1H-purine-2,6-dione
Synonyms: HOE 285, HWA 285
MF: C₁₅H₂₂N₄O₃
FW: 306.4
Purity: ≥95%
UV/Vis.: λ_{max}: 274 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Propentofylline is supplied as a solid. A stock solution may be made by dissolving the propentofylline in the solvent of choice, which should be purged with an inert gas. Propentofylline is slightly soluble in acetonitrile and chloroform.

Description

Propentofylline is a xanthine derivative and neuroprotective agent.^{1,2} It increases NGF production in primary mouse astroglia when used at concentrations ranging from 0.12 to 3.33 mM, with the maximum increase observed at 1.11 mM.¹ Propentofylline (20 µg/ml) reduces cell death induced by amyloid-β (1-42) (Aβ₄₂; Item No. 20574) in primary rat hippocampal neurons.² Intravenous infusion of propentofylline (0.01, 0.05, and 0.1 mg/kg per minute) reduces infarct volume in a rat model of ischemic brain damage induced by permanent middle cerebral artery occlusion (MCAO) when administered following MCAO.³ It inhibits cAMP phosphodiesterases, is an antagonist of adenosine A₁ and A₂ receptors, and binds to adenosine transporters.^{4,5}

References

1. Shinoda, I., Furukawa, Y., and Furukawa, S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. *Biochem. Pharmacol.* **39(11)**, 1813-1816 (1990).
2. Koriyama, Y., Chiba, K., and Mohri, T. Propentofylline protects β-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. *Eur. J. Pharmacol.* **458(3)**, 235-241 (2003).
3. Park, C.K. and Rudolph, K.A. Antiischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. *Neurosci. Lett.* **178(2)**, 235-238 (1994).
4. Nagata, K., Ogawa, T., Omosu, M., et al. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity. *Arzneimittelforschung* **35(7)**, 1034-1036 (1985).
5. Fredholm, B.B., Fastbom, J., Kvanta, A., et al. Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. *Fundam. Clin. Pharmacol.* **6(3)**, 99-111 (1992).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/19/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM